Interim Results of the Phase 1/2 PRISM Trial Evaluating 4D-150, a Dual-Transgene Intravitreal Genetic Medicine for Neovascular (Wet) Age-Related Macular Degeneration
/wp-content/uploads/4dmt_logo.svg00David Anderson/wp-content/uploads/4dmt_logo.svgDavid Anderson2023-07-28 14:54:142023-07-28 14:54:14Interim Results of the Phase 1/2 PRISM Trial Evaluating 4D-150, a Dual-Transgene Intravitreal Genetic Medicine for Neovascular (Wet) Age-Related Macular Degeneration